Mirabegron

What is Mirabegron?

Mirabegron is an active pharmaceutical ingredient primarily used in the treatment of overactive bladder (OAB) syndrome. Classified as a beta-3 adrenergic agonist, it represents a distinct class of medications that work differently from traditional anticholinergic drugs. Patients with OAB often experience sudden, uncontrollable urges to urinate (urinary urgency), frequent urination, and sometimes urge incontinence. Mirabegron helps to alleviate these bothersome symptoms by relaxing the bladder muscle, thereby increasing its capacity to store urine.

Developed to offer an alternative to anticholinergic treatments, which can be associated with side effects like dry mouth and constipation, Mirabegron provides a valuable option for individuals seeking effective management of their OAB symptoms. It is available as an extended-release tablet, designed for once-daily dosing to ensure consistent therapeutic levels throughout the day.

How Does it Work?

The mechanism of action of Mirabegron is centered on its ability to selectively activate beta-3 adrenergic receptors, which are predominantly found in the smooth muscle of the bladder wall, known as the detrusor muscle. During the urine storage phase, the detrusor muscle is relaxed, allowing the bladder to fill without increasing pressure. In individuals with overactive bladder, this muscle can become overactive, leading to involuntary contractions and the urge to urinate.

When Mirabegron binds to and activates these beta-3 receptors, it initiates a signaling pathway that leads to the relaxation of the detrusor muscle. This relaxation helps to increase the bladder's functional bladder capacity and reduce the frequency of involuntary contractions. By doing so, Mirabegron effectively reduces the symptoms of urgency, frequency, and urge incontinence associated with OAB, allowing for better bladder control and improved quality of life for patients.

Medical Uses

Mirabegron is specifically indicated for the treatment of symptoms associated with overactive bladder (OAB) in adults. These symptoms include:

• Urinary urgency: A sudden, compelling urge to pass urine that is difficult to defer.
• Urinary frequency: Urinating more often than usual.
• Urge incontinence: The involuntary leakage of urine associated with a sudden, strong urge to urinate.

It is important to note that Mirabegron is not indicated for stress incontinence or other forms of incontinence not related to detrusor overactivity. Its efficacy has been demonstrated in multiple clinical trials, showing significant improvements in these key OAB symptoms compared to placebo. Physicians may consider Mirabegron for patients who have not responded well to anticholinergic medications or who experience intolerable side effects from them, or as a first-line treatment option depending on individual patient profiles and comorbidities.

Dosage

Adult Dosage

The recommended starting dose of Mirabegron is typically 25 mg taken orally once daily. This dose can be increased to 50 mg once daily based on individual patient response and tolerability, usually after an initial period of four to eight weeks. Mirabegron extended-release tablets should be swallowed whole with water and should not be chewed, crushed, or divided. It can be taken with or without food.

Special Populations

For patients with moderate hepatic impairment (Child-Pugh Class B) or moderate renal impairment (eGFR 15 to 29 mL/min/1.73 m²), the maximum recommended dose of Mirabegron is 25 mg once daily. Mirabegron is not recommended for patients with severe hepatic impairment (Child-Pugh Class C) or severe renal impairment (eGFR < 15 mL/min/1.73 m² or patients requiring hemodialysis or peritoneal dialysis). Dose adjustments and careful monitoring are crucial in these populations to prevent accumulation and potential adverse effects.

Side Effects

Like all medications, Mirabegron can cause side effects, although not everyone experiences them. Most side effects are mild to moderate and often resolve as the body adjusts to the medication.

Common Side Effects

• Increased blood pressure (hypertension)
• Nasopharyngitis (common cold symptoms)
• Urinary tract infection (UTI)
• Headache
• Constipation
• Dry mouth
• Dizziness
• Tachycardia (increased heart rate)

Serious Side Effects

While less common, some serious side effects may occur. Patients should seek immediate medical attention if they experience:

• Severe increase in blood pressure, especially in patients with pre-existing hypertension
• Angioedema (swelling of the face, lips, tongue, or throat, which can cause difficulty breathing)
• Urinary retention (inability to empty the bladder), particularly in patients with bladder outflow obstruction or those taking anticholinergic medications.

It is important to discuss any concerns or persistent side effects with a healthcare provider.

Drug Interactions

Mirabegron is metabolized by various enzymes and can also affect the metabolism of other drugs. Awareness of potential drug interactions is important for safe and effective use.

• CYP2D6 Substrates: Mirabegron is a moderate inhibitor of CYP2D6. Co-administration with drugs primarily metabolized by CYP2D6 (e.g., metoprolol, desipramine, thioridazine, flecainide, propafenone) may increase their plasma concentrations. This may necessitate dose adjustments for the interacting drug.
• Digoxin: Mirabegron can increase the plasma concentration of digoxin. If co-administered, serum digoxin levels should be monitored and the digoxin dose adjusted as necessary.
• Warfarin: While no significant interaction has been observed, caution is advised, and INR monitoring may be prudent if Mirabegron is initiated or discontinued in patients on warfarin.
• Anticholinergics: Concomitant use with anticholinergic medications for OAB may increase the risk of urinary retention, especially in patients with bladder outflow obstruction.
• Drugs that affect blood pressure: Due to Mirabegron's potential to increase blood pressure, caution is advised when co-administering with other medications that can also affect blood pressure.

Always inform your doctor or pharmacist about all prescription, over-the-counter, and herbal supplements you are taking to avoid potential interactions.

FAQ

What is overactive bladder (OAB)?

Overactive bladder (OAB) is a common condition characterized by a sudden, strong urge to urinate that is difficult to control (urgency), often leading to frequent urination and sometimes involuntary loss of urine (urge incontinence). It results from involuntary contractions of the bladder muscle.

How long does Mirabegron take to work?

Patients may start to notice improvements in their OAB symptoms within a few weeks of starting Mirabegron. However, the full therapeutic effect may take up to 8 weeks to be achieved. Consistent daily use as prescribed is key for optimal results.

Can Mirabegron be taken with food?

Yes, Mirabegron can be taken with or without food. The extended-release tablets should be swallowed whole with water and not chewed, crushed, or divided.

Is Mirabegron safe for long-term use?

Mirabegron has been studied in long-term clinical trials and is generally considered safe and effective for long-term use in appropriate patients. Regular follow-ups with a healthcare provider are recommended to monitor for efficacy and any potential side effects.

Products containing Mirabegron are available through trusted online pharmacies. You can browse Mirabegron-based medications at ShipperVIP or Medicenter.

Summary

Mirabegron is a significant advancement in the management of overactive bladder, offering a non-anticholinergic option for patients struggling with urgency, frequency, and urge incontinence. By selectively activating beta-3 adrenergic receptors in the bladder, it promotes detrusor muscle relaxation, thereby increasing bladder capacity and reducing disruptive OAB symptoms. While generally well-tolerated, awareness of its potential side effects, particularly increased blood pressure and urinary retention, and drug interactions is crucial. As with any medication, it should be used under the guidance of a healthcare professional to ensure appropriate dosing and monitoring for optimal patient outcomes.